The ADVANTAGE seeding trial: A review of internal documents

Annals of Internal Medicine

Volumn 149, Issue 4, 2008, Pages 251-258

  Hill, Kevin P ^a   Ross, Joseph S ^b   Egilman, David S ^c   Krumholz, Harlan M ^d  

^a MCLEAN HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SHM ^*  (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; SULFONE;

CASE STUDY; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG MARKETING; LEGAL ASPECT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCIENCE; TIME SERIES ANALYSIS; CHEMICALLY INDUCED DISORDER; CONFLICT OF INTEREST; DRUG INDUSTRY; ETHICS; GASTROINTESTINAL DISEASE; HUMAN; INTERPERSONAL COMMUNICATION; MARKETING; PROFESSIONAL STANDARD; RECUMBENCY; STANDARD;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CYCLOOXYGENASE 2 INHIBITORS; DECEPTION; DISCLOSURE; DRUG INDUSTRY; ETHICS COMMITTEES, RESEARCH; GASTROINTESTINAL DISEASES; HUMANS; LACTONES; MARKETING; SULFONES;

EID: 49849101435     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-4-200808190-00006     Document Type: Review

References (32)

1. Weber LJ. Profits Before People?: Ethical Standards and the Marketing of Prescription Drugs. Bloomington, IN: Indiana Univ Pr; 2006:168.
2. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Vintage; 2005:480.
3. Kessler DA, Rose JL, Temple RJ, Schapiro R, Griffin JP. Therapeutic-class wars - drug promotion in a competitive marketplace. N Engl J Med. 1994;331: 1350-3. [PMID: 7935706]
4. Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians' guideline adherence and drug preferences. JAMA. 2006;295:2759-64. [PMID: 16788131]
5. Stephens MD. Marketing aspects of company-sponsored postmarketing surveillance studies. Drug Saf. 2003;8:1-8. [PMID: 8471183]
6. Guidelines on postmarketing surveillance. Joint committee of ABPI, BMA, CSM, and RCGP. Br Med J (Clin Res Ed). 1988;296:399-400. [PMID: 3125920]
7. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. ADVANTAGE Study Group. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med. 2003;139:539-46. [PMID: 14530224]
8. Glaser B, Strauss A. The Discovery of Grounded Theory: Strategies for Qualitative Research. Chicago: Aldine; 1967.
9. Miles MB, Huberman AM. Qualitative Data Analysis: An Expanded Sourcebook. 2nd ed. Thousand Oaks, CA: Sage; 1967.
10. Anderson SJ, Dewhirst T, Ling PM. Every document and picture tells a story: using internal corporate document reviews, semiotics, and content analysis to assess tobacco advertising. Tob Control. 2006;15:254-61. [PMID: 16728758]
11. Wayne GF, Connolly GN. How cigarette design can affect youth initiation into smoking: Camel cigarettes 1983-93. Tob Control. 2002;11 Suppl 1:I32-9. [PMID: 11893812]
12. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145:284-93. [PMID: 16908919]
13. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-12. [PMID: 18413874]
14. Yarbrough C. E-mail to Dixon M, Geba G. ADVANTAGE presentation. 14 July 1999. Bates Nos. MRK-AGV0131386 to MRK-AGV0131401. Accessed at http://dida.library.ucsf.edu/tid/vio28x10 on 17 June 2008.
15. Proceedings of the ADVANTAGE Study Investigators Meeting, Los Angeles, California, 25 March 1999. Bates Nos. MRK-APU0025051 to MRK-APU0025303. Accessed at http://dida.library.ucsf.edu/tid/vio29x10 on 17 June 2008.
16. Merck Clinical Study Report. Assessment of Differences Between Vioxx and Naproxen to Ascertain Gastrointestinal Tolerability and Effectiveness (ADVANTAGE). 29 March 2001. Bates Nos. MRK-NJ0221292 to MRK-NJ0221423. Accessed at http://dida.library.ucsf.edu/tid/vio20x10 on 17 June 2008.
17. McKines C, Sherwood L. Memo to Merck Marketing. Best Physician Program Award. 4 January 1999. Bates No. MRK-ACJ0000495. Accessed at http://dida.library.ucsf.edu/tid/vio21x10 on 17 June 2008.
18. Weiner J. Merck Marketing PowerPoint on the ADVANTAGE Trial. 16 March 1999. Bates No. MRK-ADI0017766 to MRK-ADI0017776. Accessed at http://dida.library.ucsf.edu/tid/vio24x10 on 17 June 2008.
19. Scolnick E. E-mail to Greene D. ADVANTAGE CV events tables. 7 April 2001. Bates No. MRK-ACR0009150. Accessed at http://dida.library.ucsf.edu/ tid/vio22x10 on 17 June 2008.
20. Berenson A. Evidence in Vioxx suits shows intervention by Merck officials. New York Times. 24 April 2005; A1.
21. Poucket J. E-mail to Yarbrough C. ADVANTAGE Investigators. 30 November 1999. Bates No. MRK-ACX0002964 to MRK-ACX0002968. Accessed at http://dida.library.ucsf.edu/tid/vio23x10 on 17 June 2008.
22. Higbee R. E-mail to Lindemann K, Fanelle C, and Weiner J. ADVANTAGE ideas. 19 March 1999. Bates No. MRK-ADI0024344 to MRK-ADI0024346. Accessed at http://dida.library.ucsf.edu/tid/vio26x10 on 17 June 2008.
23. Webb J. Communication to Smith B. Vioxx Seeding Study Selection. Bates No. MRK-AFB0001598. Accessed at http://dida.library.ucsf.edu/tid/vio27x10 on 17 June 2008.
24. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res. 2005;5:21. [PMID: 15762983]
25. Psaty BM, Rennie D. Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry [Editorial]. JAMA. 2006;295:2787-90. [PMID: 16788134]
26. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA. 2008;299:953-5. [PMID: 18314439]
27. Gladwell M. The Tipping Point: How Little Things Can Make a Big Difference. Boston: Little, Brown; 2000:279.
28. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-8, 2 p following 1528. [PMID: 11087881]
29. Braunstein N, Polis A. Report of specific cardiovascular outcomes of the ADVANTAGE trial [Letter]. Ann Intern Med. 2005;143:158-9. [PMID: 15968005]
30. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ. 2007;334:120-3. [PMID: 17235089]
31. Egilman DS, Presler AH. Report of specific cardiovascular outcomes of the ADVANTAGE trial [Letter]. Ann Intern Med. 2006;144:781. [PMID: 16702599]
32. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007;297:308-11. [PMID: 17227983]